BioSpace News Archive

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024, at 2:20 pm ET.

FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (“FSD Pharma” or the “Company”) today announced that through its subsidiary, HUGE Biopharma Australia Pty Ltd., it entered into agreement with iNGENu CRO Pty Ltd on March 26, 2024 to conduct “A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants”.

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced it has received the 2024 Gallup Exceptional Workplace Award.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will host a business update conference call and webcast after market close on Tuesday, April 2, 2024 beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

TellBio, Inc. announces the publication of data that shows the promise of CTCs as a prognostic biomarker for patients with prostate cancer receiving novel therapies such as radium-223.

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, alongside research collaborators, will present key findings from 11 abstracts at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5-10 (booth #915), demonstrating its commitment to advancing cancer patient care through innovative research and development initiatives.

The company behind Phexxi® vaginal gel, women’s health innovator Evofem Biosciences, Inc., announced financial results for the fourth quarter and year ended December 31, 2023.

Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) today announced that Lori Bisson, Chief Executive Officer of Autonomix, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York City, NY on Thursday, April 4, 2024 at 3:55 PM ET.

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, will present new data on the clinical utility of its Methylation Platform across the cancer continuum, and the impact of multi-cancer early detection (MCED) testing in guiding diagnostic evaluation at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, Calif., April 5-10, 2024.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R) announced today that it has submitted a Type C meeting request package to the U.S. Food & Drug Administration (“FDA”) for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long-term COVID.